Search

CAR NK-cells project, February 2025 update

A project update from Dr Ciprian Tomuleasa. We successfully designed and tested in vitro CAR T and CAR NK cells, transfected with the iCas9 suicide trigger.

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more

Meet Shaun McCann, our July volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been a member of the EHA since its beginning. I began taking part in tutorials in 2007.

Read more

Meet Shaun McCann, our July volunteer of the month

Can you tell us what you do for EHA and when you started?
I have been a member of the EHA since its beginning. I began taking part in tutorials in 2007.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more